Skip to content

Scientists and clinicians must challenge HIV-related stigma and ensure enabling legal and policy environments, IAS conference hears

IAS 2013 plenary speaker Prof. Aziza Ahmed of Northeastern University, Boston. Photo © International AIDS Society/Marcus Rose/Workers' Photos

Efavirenz in children: WHO dosing guidelines raise the risk of side-effects in Thai children

Non-African middle-income countries pay four times more for ARVs than African middle-income countries

Andrew Hill / Photo ©International AIDS Society/Steve Forrest/Workers' Photos

Darunavir/ritonavir safe and effective for younger children

Lower-dose lopinavir/ritonavir reduces side-effects, maintains viral control in Thai children

Dr Thanyawee Puthanakit speaking at IAS 2013. Photo ©International AIDS Society/Marcus Rose/Workers' Photos

Magical thinking? FEM-PrEP trial may have failed because participants used testing as prevention

Malaysia’s harm reduction programmes are preventing infections and saving money, but reaching far too few people who inject drugs

Ragunath Kesavan of the Malaysian Bar Council speaking at IAS 2013. Photo©International AIDS Society/Marcus Rose/Workers' Photos

Fibroscan accurately predicts liver decompensation and death in HIV/HCV co-infected people

Juan Macías of Hospital Universitario de Valme in Seville, Spain. © Liz Highleyman / hivandhepatitis.com

Studies look at bone changes during second-line therapy, fractures, and HIV- and HCV-related bone loss

Jennifer Hoy of the Alfred Hospital, Melbourne, speaking at an IAS press conference. Photo©International AIDS Society/Steve Forrest/Workers' Photos